Literature DB >> 16887373

Solitary plasmacytoma of bone in two successfully treated cats.

Paul J Mellor1, Gerry A Polton, Malcolm Brearley, Sean Haugland, Ken C Smith, Tim J Scase, Pauline E McNeil, Andrew Holloway, Joy Archer, Roger M Powell, Elizabeth J Villiers, Mike E Herrtage, David J Argyle, Michael J Day.   

Abstract

This is the first report of feline solitary plasmacytoma of bone. We describe the clinical, clinico-pathological, radiographic and pathological findings of two successfully treated cats with long-term follow-up. The first case presented with spinal pain and neurological deficits. Radiographs demonstrated sclerosis of lumbar vertebra L6 and a myelogram confirmed interference to flow of contrast in the L4-7 region. A biopsy of L6 revealed neoplastic plasma cell infiltration. There was no evidence of paraproteinaemia on serum protein electrophoresis. The cat underwent hypofractionated megavoltage radiotherapy. Clinical signs resolved completely and 4 years after diagnosis the cat remains well and has no electrophoretically detectable paraproteinaemia. The second case presented with neurological deficits of the tail and spinal radiographs revealed extensive osteolysis of the sacrum. A biopsy of sacral bone demonstrated neoplastic plasma cell infiltration. The animal was normoglobulinaemic. The cat improved clinically with induction chemotherapy (melphalan and methylprednisolone). The same chemotherapeutics were continued at maintenance doses for 4.3 years, at which time there was recurrence of neurological deficits and a palpable sacral mass. Cytological examination of a fine needle aspirate confirmed recurrence of plasma cell neoplasia. A low concentration monoclonal paraproteinaemia was detected. Vincristine was administered resulting in resolution of neurological deficits and a palpably smaller sacral mass. Eighteen months into vincristine therapy, there was recurrence of clinical signs and the cat was euthanased, more than 6 years after the initial diagnosis.

Entities:  

Mesh:

Year:  2006        PMID: 16887373     DOI: 10.1016/j.jfms.2006.05.010

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  1 in total

1.  Melphalan, alone or conjugated to an FSH-β peptide, kills murine testicular cells in vitro and transiently suppresses murine spermatogenesis in vivo.

Authors:  John K Amory; SungWoo Hong; Xiaozhong Yu; Charles H Muller; Elaine Faustman; Alex Goldstein
Journal:  Theriogenology       Date:  2014-03-27       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.